Global WholeHealth Partners Corp (OTC:GWHP) Receives a Second Order for 10,000 Tests From Salud Previa of Tijuana, MX; Salud Previa has Ordered Over 30,000 Tests Now; Tests Sold Were Pregnancy Tests, Drug Tests, Dengue Fever, TB and COVID

Rhea-AI Summary

Global WholeHealth Partners Corp (OTC:GWHP) announced a partnership with Salud Previa to sell 500,000 COVID-19 tests, including antigen and antibody tests capable of detecting the Delta variant. The company offers one of the largest lines of COVID-19 tests and holds FDA approvals for 56 products, with many available for over-the-counter use. Global WholeHealth emphasizes the need for faster testing and results to combat the ongoing pandemic.

Positive

• Partnership with Salud Previa to sell 500,000 COVID-19 tests.
• Offers tests capable of detecting all identified SARS-CoV-2 variants.
• 56 FDA-approved products, enhancing market position.

Negative

• Dependence on third-party suppliers could impact production capabilities.
• Potential need for additional capital may dilute existing shares.

San Clemente, CA, July 20, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Global WholeHealth Partners Corp (OTC:GWHP) will be selling several types of tests to Salud Previa. Global is on its way to selling the 500,000 tests of Salud Previa's annual projection.

The Global WholeHealth Partners Corp (OTC:GWHP) COVID 19 Antigen and Antibody test can pick up the DELTA Variant. It is important to continue to test to help stop this Virus.

Global WholeHealth Partners Corp. (OTC: GWHP) offers one of the largest lines of COVID 19 tests. Global WholeHealth Partners Corp (OTC: GWHP) states that the Antibody IgG/IgM tests that they offer are capable of detecting all the current identified SARS-CoV-2 viruses.  The strains identified in the United Kingdom (B.1.1.7), South Africa (B.1.351), and Brazil (P.1) strain contain multiple mutations, most reflected in the S gene, which encodes the spike protein. Global understands the need to be ahead of the virus to conquer the virus.

Global WholeHealth Partners recognizes that there is a crucial need for faster testing and faster results when it comes to fighting the COVID. Global WholeHealth Partners knows that the quicker the test results can be reviewed by a Front-Line Healthcare Worker, the quicker we can stop the spread of this disease.

Global WholeHealth Partners Corp. provides cutting edge technology using In-vitro Diagnostic (IVD) Real-Time PCR Machines for detection of SARS-CoV-2 IgM/IgG antibodies in human serum, plasma, or whole blood. It has led the fight against vector borne terminal diseases such as Ebola, ZIKA, Dengue, Malaria, Influenza and Tuberculosis, Corona Viruses, and among other vector borne diseases with an FDA Certificate of Exportability (2260-11-2019).  The company was founded on March 7, 2013 and is headquartered in San Clemente, CA.

GWHP develops, manufactures, and markets in vitro diagnostic (IVD) tests for OTC, or consumer-use as well as professional rapid diagnostic point-of-care (POC) test kits for hospitals, physicians’ offices, and medical clinics in the US and abroad. Notably, The Company offers 56 products FDA approved and many are Approved for OTC use, and over 15 POC products approved by the CLIA WAIVED FDA.

Media Contact:

Name: Charles Strongo,

CEO, Global WholeHealth Partners Corp.

Email: Sales@gwhpcorp.com

Call to buy Tests or Vaccines:

Phone for Sales: 877-568-4947

www.gwhpcorp.com

Forward-Looking Statements

This press release contains "forward-looking statements.”  Such statements may be preceded by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company's control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) market acceptance of our existing and new products, (ii) negative clinical trial results or lengthy product delays in key markets, (iii) an inability to secure regulatory approvals for the sale of our products, (iv) intense competition in the medical device industry from much larger, multinational companies, (v) product liability claims, (vi) product malfunctions, (vii) our limited manufacturing capabilities and reliance on subcontractors for assistance, (viii) insufficient or inadequate reimbursement by governmental and other third party payers for our products, (ix) our efforts to successfully obtain and maintain intellectual property protection covering our products, which may not be successful, (x) legislative or regulatory reform of the healthcare system in both the U.S. and foreign jurisdictions, (xi) our reliance on single suppliers for certain product components, (xii) the fact that we will need to raise additional capital to meet our business requirements in the future and that such capital raising may be costly, dilutive or difficult to obtain and (xiii) the fact that we conduct business in multiple foreign jurisdictions, exposing us to foreign currency exchange rate fluctuations, logistical and communications challenges, burdens and costs of compliance with foreign laws and political and economic instability in each jurisdiction. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's filings with the Securities and Exchange Commission (SEC), including the Company's Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC's web site at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.

FAQ

What recent partnership did GWHP announce?

Global WholeHealth Partners Corp announced a partnership with Salud Previa to sell 500,000 COVID-19 tests.

What types of tests will GWHP provide?

GWHP will provide COVID-19 antigen and antibody tests capable of detecting the Delta variant.

How many FDA-approved products does GWHP offer?

GWHP offers 56 FDA-approved products, many of which are available for over-the-counter use.

What is the significance of the tests GWHP is selling?

The tests are crucial for faster detection and response to COVID-19, particularly in combating variant strains.

What financial risks does GWHP face?

GWHP faces risks such as reliance on third-party suppliers and potential capital dilution.